Abstract: Process information is caused to have an input source and access rights to resources, and by identifying from what input source a process has arisen and from what input source a command request originates, foreign process and normal processes are distinguished. By limiting access to system resources from foreign processes, the system is protected.

Abstract: The present invention provides a pharmaceutical composition which is effective for treating multiple myeloma. The present invention relates to a pharmaceutical composition comprising a combination of an antibody composition which specifically binds to ganglioside GM2 or an antibody fragment thereof and at least one agent.

Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

Abstract: The present invention provides an agent which is effective to a patient who is administered by an agent comprising anti-CD20 antibody as an active ingredient.

Abstract: In order to obtain high therapeutic effects in treating malignant tumors, particularly melanoma, a new therapeutic method having less side effects, or a new therapeutic method which can provide further high therapeutic effects at conventional doses of agents has been desired. An object of the present invention is to provide a medicament which can provide higher therapeutic effects than any one of a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof alone, and a substance which activates an immunocomponent cell and a substance having an antitumor activity alone, by combining a gene recombinant antibody against ganglioside GD3 or the antibody fragment thereof with at least one of a substance which activates an immunocomponent cell and a substance having an antitumor activity. Also, the medicament is expected to relieve side effects which were problems in the case of administration of individual single agents.

Abstract: In ultramarine blue, or a blue pigmented phosphor in which ultramarine blue is a constituent, a coating of organic silicon compound is formed on the surface of the ultramarine blue pigment. This coating prevents fading of the ultramarine blue during the manufacture of cathode ray tubes.

Abstract: A green-emitting phosphor is activated by cerium and terbium and is represented by the general formula:(Re.sub.1-a-b-3c Tb.sub.a Ce.sub.b A.sub.3c).sub.2 O.sub.3.mP.sub.2 O.sub.5.nSiO.sub.2wherein Re is at least one member selected from the group consisting of yttrium, lanthanum, and gadolinium; A is at least one member selected from the group consisting of lithium (Li), sodium (Na), potassium (K), rubidium (Rb), and cesium (Cs); and a>0, b>0, c>0, 0<a+b+3c<1, 1.times.10.sup.-5 .ltoreq.c.ltoreq.5.times.10.sup.-2, m>0, and n>0.The green-emitting phosphor of the invention may be widely applied to fluorescent lamps for copying machine light sources, or high luminous efficacy and high color rendering property fluorescent lamps such as three peak emission system fluorescent lamps.

Abstract: A fluorescent lamp having a phosphor film comprising:a blue-emitting phosphor consisting essentially of at least one divalent europium activated haloborophosphate phosphor having the general formula:x(M.sub.1-p.Eu.sub.p.O).yP.sub.2 O.sub.5.aM'X.sub.2.bB.sub.2 O.sub.3wherein M and M' are independently at least one of Sr, Ca and Ba; X is at least one of Cl, F and Br; and 2.7.ltoreq.x.ltoreq.3.3, 0.50.ltoreq.y.ltoreq.1.50, 0.10.ltoreq.a.ltoreq.0.50, 0.01.ltoreq.b.ltoreq.0.50, and 0.001.ltoreq.p.ltoreq.0.20;a green-emitting phosphor consisting essentially of a cerium and terbium activated silicophosphate phosphor of the general formula:(Re.sub.1-c-d-3e Tb.sub.c Ce.sub.d A.sub.3e).sub.2 O.sub.3.qP.sub.2 O.sub.5.rSiO.sub.2wherein Re is at least one of Y, La and Gd; A is at least one of Li, Na, K, Rb, and Cs; and 0<c, 0<d, 5.times.10.sup.-2 .gtoreq.e.gtoreq.1.times.10.sup.

Abstract: Disclosed is a fluorescent lamp which comprises a mixture of a phosphor (i) comprising an alkaline earth metal halophosphate phosphor activated with divalent europium, represented by the general formula:M.sub.5-x X(PO.sub.4).sub.3 :Eu.sup.2+ (x)wherein M consists of Ba, Ca and Mg, containing 3 to 4.5 gram-atom of Ba, 0.5 to 2 gram-atom of Ca and 0.01 to 1 gram-atom of Mg each; X is one or more of F, Cl or Br; and 0.01<x.ltoreq.0.2and having the emission peak at the wavelength region of 480 to 500 nm, and a phosphor (ii) having the emission peak at the wavelength region of 620 to 640 nm and having the half width of 120 to 160 nm.

Abstract: Disclosed is a blue-green emitting halophosphate phosphor activated with divalent europium, which is represented by the general formula:M.sub.5-x X(PO.sub.4).sub.3 :Eu.sup.2+.sub.(x)wherein M consists of Ba, Ca and Mg, X is one or more of F, Cl or Br, and x is a positive number of less than 5.

Abstract: Disclosed is a method for surface treatment of phosphor particles which comprises forming a continuous film of silicon dioxide on the surface of each phosphor particle by treating the phosphor particle with a solution containing an aqueous solution of organic alkali and silicon dioxide dissolved therein.